PARKINSON S DISEASE AND PARKINSONISM. Dr Phil Wood Geriatrician, Waitemata DHB Clinical Unit Leader, Waikato DHB



Similar documents
Parkinson s Disease - A Junior Doctor s Survival Guide

What is PD? Dr Catherine Dotchin MD MRCP Consultant Geriatrician

Dementia & Movement Disorders

Management of Parkinson s Disease in Primary Care

Parkinson s Disease and Dementia. Dr N Samaniego Consultant Physician and Geriatrician

Parkinson's s disease - a

CENTRAL NERVOUS SYSTEM MANAGEMENT OF PARKINSON S DISEASE

Chapter 28. Drug Treatment of Parkinson s Disease

Understanding Parkinson s Disease

Mr James Garrard University of Leicester May 2014

UNIFIED PARKINSON'S DISEASE RATING SCALE

Lewy body dementia Referral for a Diagnosis

Clinical Psychopharmacology

NEUROIMAGING in Parkinsonian Syndromes

Hoehn and Yahr Staging of Parkinson's Disease

SIGN. Diagnosis and pharmacological management of Parkinson s disease. January A national clinical guideline

III./ Parkinsonian syndrome (parkinsonism, atypical parkinsonian disorders) in neurodegenerative diseases

Emergency Room Treatment of Psychosis

Parkinson s Disease: General Information

Parkinson s Disease (PD)

PARKINSON S DISEASE IN LONG-TERM-CARE SETTINGS

Nursing Care of Patients with Movement Disorders. Catholic Health 2 nd Annual Neurorehab Symposium November 1, 2014

Journal Club. Parkinsonismo iatrogeno

Summary of the risk management plan (RMP) for Aripiprazole Pharmathen (aripiprazole)

ABC s of Parkinson s Disease 4/29/15 Karen Parenti, MS, PsyD

Parkinson s disease. 14 June 2012

How To Treat Aphasic Depression

UNIFIED PARKINSON'S DISEASE DATA FORM. 1 Mentation. Date: On Off On Off On Off On Off On Off On Off On Off On Off

The majority of parkinsonism (approx. 80%) is due to idiopathic PD other causes include drug therapy (Table 1),toxins and trauma.

GLOSSARY OF TERMS. This glossary explains the terms and words often used in association with Parkinson s.

Doncaster & Bassetlaw Medicines Formulary

Parkinson s Disease and Tremors

An Introduction to Lewy Body Dementia

Multiple System Atrophy guide (

PARKINSON S DISEASE INTRODUCTION. Parkinson s disease is defined as a disease of the nervous system that affects voluntary movement.

Prevalence of Parkinsonism and its aetiological subtypes within patients with movement disorders

Diagnosing Parkinson s disease (PD) in

Parkinson s Disease Symptoms Guide

Clinical Research in Parkinson s Disease: The Advances, Challenges, and Importance of Rater Training

Anti-Parkinsonism Drugs

Welcome to the Medical Risk Webinar: a taster of Assessing and Managing Medical Risk for Insurers courses. 26 April 2013

Personal Health Record

Sinemet (Parkinson's Disease) - Forecast and Market Analysis to 2022

Multiple System Atrophy

PARKINSONISM. akinetic-rigid syndrome

Steps to getting a diagnosis: Finding out if it s Alzheimer s Disease.

Parkinson's disease. Definition. Symptoms

Part 1 of a 6-Part Series

MOTION AND E-MOTION. Andrea Cavanna MD PhD FRCP

SLEEP AND PARKINSON S DISEASE

Recognition and Treatment of Depression in Parkinson s Disease

Conjoint Professor Brian Draper

2016 Programs & Information

Chapter 18 Drugs Used for Psychoses Learning Objectives Identify signs and symptoms of psychotic behavior Describe major indications for the use of

Clinical characteristics of neuroleptic-induced parkinsonism

EBM Parkinson s Diseases

PARTNERS IN PARKINSON S. Parkinson s Disease Guide

Mental health issues in the elderly. January 28th 2008 Presented by Éric R. Thériault

Neuropharmacology I Parkinson s Disease and Movement Disorders

Rörelserubbningar och Parkinson, hur svårt kan det vara. En översikt och problematisering av en folksjukdom Örjan Skogar, MD,PhD

SLEEP DIFFICULTIES AND PARKINSON S DISEASE Julie H. Carter, R.N., M.S., A.N.P.

Current evidence suggests that Parkinson s tends to develop

Contemporary Psychiatric-Mental Health Nursing. Assessing the Effectiveness of Medications. Administering Medications

ASSESSMENT AND MANAGEMENT OF PSYCHOSIS IN PERSONS WITH DEMENTIA

Psychosis Psychosis-substance use Bipolar Affective Disorder Programmes EASY JCEP EPISO Prodrome

Management of Parkinson s disease and co-existent health problems is a long journey, requiring a multidisciplinary team approach.

How to identify, approach and assist employees with young onset dementia: A guide for employers

Neurological System Best Practice Documentation

1: Motor neurone disease (MND)

Treatments for Major Depression. Drug Treatments The two (2) classes of drugs that are typical antidepressants are:

A Manic Episode is defined by a distinct period during which there is an abnormally and persistently elevated, expansive, or irritable mood.

Below, this letter outlines [patient name] s medical history, prognosis, and treatment rationale.

Meeting Report: XX WFN World Congress on Parkinson s Disease and Related Disorders

Parkinson s Disease: Factsheet

Antipsychotic drug prescription for patients with dementia in long-term care. A practice guideline for physicians and caregivers

Diagnosis and Treatment of Parkinson s Disease: A Systematic Review of the Literature

Drug-induced movement

A GUIDE FOR THE NEW PATIENT. supported by the Neurological Foundation


Parkinsonism is an umbrella term used to cover a range of conditions.

Social Security Disability Insurance and young onset dementia: A guide for employers and employees

Unmet Needs for Parkinson s Disease Therapeutics

Depression and Anxiety in Parkinson s disease

DRUG-INDUCED COMPULSIVE BEHAVIOUR IN PARKINSON S: CLINICAL AND LEGAL IMPLICATIONS ADRIAN CARTER AND WAYNE HALL

DEPRESSION CARE PROCESS STEP EXPECTATIONS RATIONALE

9/20/2010. The eye doesn t see what the mind doesn t know. Sir William Osler

CLINICAL PRACTICE GUIDELINES FOR PHYSICAL THERAPY IN PATIENTS WITH PARKINSON'S DISEASE

Doctor I can t walk properly - a guided walk around some gait problems

Understanding Antipsychotic Medications

Neuropsychological Testing Appointment

What You Need to Know About Xenazine

Summary of the risk management plan (RMP) for Rasagiline ratiopharm (rasagiline)

Sleep and Night-time Problems in Parkinson s What are the causes of sleep disruption in Parkinson s? Parkinson s Disease Society

COMPASS Therapeutic Notes on Management of Parkinson s Disease

Cerebellum and Basal Ganglia

Patients with dementia and other types of structural brain injury are predisposed to delirium (i.e., abrupt onset, temporary confusion caused by

DEMENTIA EDUCATION & TRAINING PROGRAM

Dementia with Lewy bodies

Drugs PSYCHOSIS. Depression. Stress Medical Illness. Mania. Schizophrenia

Headaches in Children How to Manage Difficult Headaches

Transcription:

PARKINSON S DISEASE AND PARKINSONISM Dr Phil Wood Geriatrician, Waitemata DHB Clinical Unit Leader, Waikato DHB

OUTLINE Covering:- Why this is an important area of Medical and Psychiatric care The variety of Clinical Presentation How to ask the right questions How to do an appropriate examination What investigations may be helpful Routine and other management options Adverse effects of Management Special areas of interest such as drug induced parkinsonism, Lewy Body Disease, Vascular, PSP etc etc etc

CONTEXT Probability Diseases causing parkinsonism Drugs treating and contributing to parkinsonism Prevalence PD (ICD-10= G20) = 2 nd most prevalent Neurodegenerative disease after AD 0.3% total population, 1% >60yr, 4% >80yrs Burden of disease and burden of treatment Available pharmaceutical treatments are numerous and readily available The Obvious cases are Easy!

CLINICAL PRESENTATION Usual Features Remember the Triad (2 out of 4) Tremor Bradykinesia (slowing) Rigidity Postural instability Note, can and often will be accompanied by Neuropsychiatric syndromes Autonomic effects Support Features Unilateral onset. Rest tremor present. Progressive disorder. Persistent asymmetry affecting the side of onset most. Excellent response (70-100%) to L- dopa. Severe L-dopa-induced chorea. L-dopa response for five years or more. Clinical course of ten years or more. Hyposmia. Visual hallucinations

TREMOR 70% will have tremor at presentation Typical tremor = At Rest Usually asymmetrical (a unilateral rest tremor in the foot is almost pathognomonic) Relatively slow, regular, more coarse than Essential Tremor Rarely constant Progressive

BRADYKINESIA Subtle at first May start with fine motor skills (doing up buttons, tying shoelaces etc) psychological inertia Affects rapid alternating movements Can be dependent on emotion ( SHOUT Fire - kinesia paradoxical) Difficulty with initiation of and maintaining smooth movement (producing some curious yet classical phenomena and tricky treatments!

RIGIDITY Muscle stiffness Can be almost cramp like and uncomfortable Often Axial (legs / neck / back)

VIDEO

PARKINSON S DISEASE SUSPECT AN ALTERNATIVE DIAGNOSIS IF Rapidly progressive course Lack of dopaminergic response Early postural instability Cerebellar signs Early autonomic features Pyramidal signs Rapidly progressing or early dementia Supranuclear gaze palsy, slowed saccades Early falls Symmetry of motor manifestations Lack of tremor

UPDRS Research pedigree but a useful tool to organise examination findings. 4 Parts I = Mentation, Behaviour and Mood (Enquiry) II = Activities of Daily living (Enquiry) III = Motor Examination (Observation) IV = Complications of therapy (Observation)

Intellectual impairment Thought disorder Nil Vivid dreams Benign hallucinations, retained insight Frequent, delusional, with reduced insight Persistent, psychosis, unable to care for self Depression Motivation/initiative MENTATION, BEHAVIOUR AND MOOD

ACTIVITIES OF DAILY LIVING Speech Salivation Swallowing Handwriting Cutting Food and Handling Utensils Dressing Hygiene Turning in Bed Falls Freezing Walking Tremor Sensory complaints

MOTOR EXAMINATION Speech Facial Expression Tremor at rest Action or postural tremor Rigidity Finger Taps Hand movements Rapid alternating movements Hands Leg Agility Arising from Chair Posture Gait Postural stability Body Bradykinesia

INVESTIGATIONS CT or MRI brain scan: For patients who fail to respond to therapeutic doses of L-dopa (at least 600 mg/day) administered for 12 weeks. MRI scanning is needed to exclude rare secondary causes (eg, supratentorial tumours and normal pressure hydrocephalus) and extensive subcortical vascular pathology. [1] Functional MRI and CT imaging are useful research tools. Blood flow changes monitored by these methods and correlated with functional disability are providing useful clues as to the structural abnormalities which cause Parkinsonism and PD. [10]7] PET scanning with fluorodopa can localise dopamine deficiency in the basal ganglia, while autonomic tests and sphincter electromyography may support a diagnosis of multiple system atrophy. Genetic testing may be required - eg, Huntington's gene. Fewer than 5% of all PD cases are caused by known single-gene mutations. [7] Olfactory testing to help differentiate PD from other Parkinsonian disorders. [7] Further investigations for young-onset or atypical disease may include measurement of ceruloplasmin levels (Wilson's disease) and syphilis serology.

I-FP-CIT PET imaging in two DIP patients. DAT uptake was normal and symmetric in the bilateral striatum in a pure DIP patient (A), whereas it decreased severely in the right striatum in a patient who was diagnosed with PD unmasked by DRBAs (B). DAT: dopamine transpoter, DIP: drug-induced parkinsonism, DRBA: dopamine receptor blocking agents, PD: Parkinson's disease

COMPLICATIONS OF THERAPY Confusion, hallucinations, delusions, agitation, psychosis. Nausea, dizziness, headache, orthostatic hypotension Motor fluctuations Dopamine dysregulation syndrome a cyclical mood disorder with hypomania and possible manic psychosis Impulse control disorders including hypersexuality and pathologic gambling may occur Patients on dopamine agonists may develop impulse control problems The adverse effects of dopamine agonist are similar to levodopa. Peripheral edema is more common with agonists Elderly and demented patients are more susceptible to psychiatric side effects sleep attacks

ROUTINE MANAGEMENT Dopaminergic agents as in Sinamet / Madopar in various preparations Primary Dopa agonists Ropinerole Pramipexole Pergolide Bromocryptine Anticholinergics Adjuvant agents COMPT inhibitors

ADVERSE EVENTS AND LATE DISEASE PHENOMENON

PARKINSONISM Secondary parkinsonism, ICD-10 = G21 Drug induced Trauma Vascular NPH Other conditions PD Plus Lewy Body Disease Progressive Supranuclear Palsy - SRO Multisystem Atrophy

DRUG INDUCED PARKINSONISM Suggestive features:- Use of potentially causative medications prior to onset 7% of people with parkinsonism have a hy of relevant drug exposure %0% occur <1 month Acute / rapid onset of levodopa unresponsive motor pd Symmetrical Improves after medication discontinuation / change Presence of Tardive Dyskinesia Normal DaT binding on PET Reduced raclopride binding on PET

MANAGEMENT OF PARKINSONISM Stop the offending agent? Usually effective? but potentially risky! Swap to less toxic medications Anticholinergics including trihexyphenidyl, benztropine, amantadine, and levodopa have been empirically tested for their ability to relieve symptoms of DIP, but this has produced no clear evidence of their effects in DIP patients